Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangmin Zhenke Granules
- Development stage
- Unknown
- Lead developer
- Tianjin Rohto Chinese Medicine
- Administration
- Oral
01
Overview
Kangmin Zhenke Granules is a Traditional Chinese Medicine (TCM) product developed by Tianjin Rohto Chinese Medicine for the treatment of cough variant asthma (CVA). It is specifically formulated to address the TCM pattern of 'wind-evil stagnating in lung' (风邪犯肺证), a condition characterized by chronic, paroxysmal coughing often triggered by allergens or cold air. The formulation is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in China to assess its efficacy in reducing cough symptoms and improving lung function in adult patients.
- Other names
- 抗敏止咳颗粒Kangmin Zhike Granules
02
Targets
DNAHSD11B2 (11β-HSD2)
Beyond the preview
Go deeper on Kangmin Zhenke Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangmin Zhenke Granules.